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COST OF ANKYLOSING SPONDYLITIS IN CZECH
REPUBLIC—DIRECT AND INDIRECT COSTS
Doležal T1, Skoupá J2, Cerna V2
1Charles University, Prague, Czech Republic, 2Pharma Projects, Prague,
Czech Republic
OBJECTIVES: Ankylosing spondylitis (prevalence 1% of popu-
lation) is a chronic inﬂammatory progressive disease character-
ised by pain, joint stiffness, and gradual loss of mobility leading
to severe functional impairment. There are no cost-of-illness data
available in Czech Republic or in Eastern Europe. To assess direct
and indirect costs of ankylosing spondylitis we have analysed the
data from a large patient cohort study. METHODS: Data of
1008 patients (average age 50.2 years) with ankylosing spondyli-
tis were analysed. Patients were enrolled in a patientxs organi-
sation survey named BÉÏA. Data on health care consumption and
productivity loss were collected. For calculation of indirect cost
the friction cost approach was applied. RESULTS: The average
time from diagnosis was 23 years; 61% were male. Two thirds of
patients were disabled and unable to work. The mean annual
direct cost per patient is estimated at 1259 EUR (49%) and the
indirect cost due to lost work capacity is 1314 EUR (51%). The
major contributors to the total direct costs were physiotherapy,
spa and rehabilitation clinics (67% of direct costs). Drug treat-
ment contributed to 22% and hospital admissions to 5% of
direct costs. CONCLUSION: The annual total direct plus indi-
rect costs of one patient with ankylosing spondylitis in Czech
Republic were 2573 EUR. The share of direct and indirect costs
was almost equal. Our ﬁndings provide information on the
burden of disease and a baseline for cost-effectiveness evaluation
of new costly treatments.
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A SYSTEMATIC REVIEW OFTHE GLOBAL COST-OF-ILLNESS
OF RHEUMATOID ARTHRITIS
Richard L1, Brown M2
1UCB Celltech, Slough, UK, 2UCB, Slough, UK
OBJECTIVES: To systematically review the current literature
relating to the cost-of-illness (COI) of rheumatoid arthritis (RA).
METHODS: Medline, Embase, BIOSIS, Derwent Drug File, the
Cochrane library and NHS-EED were searched on 12th March
2007. Original studies (2002-present) reporting COI data were
included after a two-stage review process. Bibliographies of
included studies were also searched for additional citations. Data
were extracted into predeﬁned extraction grids and were analy-
sed using Microsoft Excel. RESULTS: Nine hundred and nine
unique citations were retrieved. Of these, 9 studies presented
COI results. These studies were conducted in 5 different coun-
tries (Australia, France, Germany, Sweden, and the US) from
2003–2007. Six studies adopted a societal perspective by includ-
ing direct medical and non-medical costs and indirect costs.
Patient populations across the studies ranged from only early RA
(<12 months from disease onset) to all RA patients. The use of
biological agents (including inﬂiximab, etanercept, and anakinra)
was assessed in only 3 of these studies. Annual direct costs
ranged between €3000 and €4000 in all European countries.
Lower annual direct costs were reported in the Australian analy-
sis as a result of the inclusion of all Australian adults with RA,
while substantially higher costs were found in a US study. This
could be attributed to the higher costs of medications that
included anti-TNF therapies. In terms of components of direct
costs, medications and hospitalisations were generally the cat-
egories associated with the highest costs. Indirect costs exceeded
direct costs in 5 of the 6 analyses. These ranged between 2 and 4
times the direct costs. Finally, a statistically signiﬁcant positive
correlation was found in most studies between total RA costs and
disease severity. CONCLUSION: This review of recently pub-
lished COI analyses found that RA is associated with signiﬁcant
direct and indirect costs, with the economic burden being highly
dependent on the level of functional disability.
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DEPRESSION AMONG RHEUMATOID ARTHRITIS PATIENTS
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OBJECTIVES: To examine the resource utilization and direct
costs of care associated with comorbid cardiovascular disease
(CVD) and depression among prevalent rheumatoid arthritis
(RA) patients using retrospective health care claims data.
METHODS: Patients  18 years of age with a diagnosis of RA
January 1, 2002-December 31, 2004 were selected. The date of
the ﬁrst observed claim with an RA diagnosis following a one
year period of health plan enrollment was the “index date.”
Patients had 12-month pre-index and follow-up periods. Patients
were also required to have a diagnosis of RA and RA-related
treatment during pre-index. Based upon pre-index utilization,
patients were classiﬁed into mutually exclusive diagnosis groups:
RA with comorbid depression; RA with comorbid CVD; RA
with comorbid CVD and depression; RA alone. Annual utiliza-
tion and costs were calculated; generalized linear models (GLM)
were undertaken, controlling for demographic and clinical char-
acteristics. Analyses focused on differences in costs among
RA only vs. comorbid diagnosis groups. RESULTS: A total of
8916 patients had RA alone (86.6%), 608 had RA + CVD
(5.9%), 716 had RA + depression (7.0%), and 58 had
RA + CVD + depression (0.5%). Mean age varied by cohort
group with RA + CVD tending to be older (RA + CVD: 59 years;
RA + depression: 50 years; RA + CVD + depression: 53 years;
RA alone: 51 years). A signiﬁcantly lower proportion of patients
with RA alone had a RA-related hospitalization stay during
follow-up (5.4%) compared with other groups (RA + CVD:
9.4%; RA + depression: 0.001). In GLM modeling, adjusted
mean < 9.2%; RA + CVD + depression: 15.5%, all p annual
costs were highest for RA + CVD ($14,328) followed by
RA + CVD + depression ($13,276), RA + depression ($12,270),
and RA alone ($11,522). CONCLUSION: A signiﬁcant portion
of prevalent RA patients has comorbid CVD and/or depression
(13.4%). Comorbid depression and cardiovascular events are
associated with signiﬁcant increase in not only the annual total
medical costs, but there may also be associated increases in
RA-related utilization.
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SC FORTHETREATMENT OF RHEUMATOID ARTHRITIS:AN
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OBJECTIVES: To compare the effectiveness of oral leﬂunomide
(Arava®) and subcutaneous metotrexate (Metoject®) using the
Number Needed to Treat (NNTs), a measure supported by the
Evidence Based Medicine approach. The effectiveness results
have been combined with Spanish annual costs to assess the
economic impact of these treatments. METHODS: An event has
been deﬁned as non-responder patient according to ACR20 and
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ACR50 criteria with each of the drugs compared. NNTs calcu-
lated as the inverse of the Absolute Risk Reduction, have been
derived using results according to intention-to-treat from a ran-
domised controlled trial (US310) comparing 20 mg daily of
leﬂunomide with 7.15–15 mg weekly of metotrexate, adminis-
tered during 1 year. Considered annual treatment costs related
with the costs of the drug administered the consultations and lab
tests performed for routine monitoring, according to the infor-
mation provided by the manufactures in their summary of
product characteristics. Unitary costs have been obtained from
Spanish cost databases. RESULTS: Using the ACR20 criteria
NNTs with leﬂunomide and metotrexate SC are 4 (95% CI
2.56–7.71) and 5 (95% CI 3.03–14.3) respectively. Using the
ACR50 criteria NNTs are 4 (95% CI 2.72–6.54) and 7 (95% CI
4.03–19.3). The annual cost of each treatment per patient-year
(drugs and monitoring) equals 1793.3€ in case of leﬂunomide
and 2149.2€ for metotrexate SC. Combining these results the
cost of a controlled patient according to ACR20 amounts 7173€
for leﬂunomide and 10,746€ for metotrexate SC. Results accord-
ing to ACR50 equals 7173€ and 15044€ respectively. CONCLU-
SION: From the Spanish National Health System perspective and
effectiveness measured as respondent according to ACR20 the
use of leﬂunomide for patients with Rheumatoid Arthritis could
achieve important cost savings compared with the administration
of metotrexate SC. The savings could be even more important
when the ACR50 response criteria are considered.
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ASSOCIATION BETWEEN DOSE CHANGES AND HEALTH
CARE COSTS IN RHEUMATOID ARTHRITIS PATIENTS WHO
RECEIVED INFLIXIMABTHERAPY
Nair KV1,Tang B2,Van Den Bos J3, Zhang V3, Naim A2, Rahman MI2
1University of Colorado at Denver and the Health Sciences Center,
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OBJECTIVES: To explore the relationship between dose changes
and costs in rheumatoid arthritis (RA) patients treated with
inﬂiximab. METHODS: A 5-year retrospective study using the
Medstat MarketScan database was conducted. The sample con-
sisted of patients who had a diagnosis of RA (ICD-9 = 714.xx);
at least three administrations of inﬂiximab between 1999 and
2005; no history of using anti-tumor necrosis factors for at least
6-month prior to the index infusion, and continuous enrollment
for at least 12 months after the index infusion. Per-member-per-
month (PMPM) medical and pharmacy costs were compared
among three patient cohorts: increase, decrease, and no change in
dose between the ﬁrst and the last doses in the study period.
Differences in costs were conducted controlling for age, gender,
and a health risk-adjuster score. The cost of adverse events could
not be identiﬁed separately in this analysis. RESULTS: Among
2318 patients included in the study, 685 (29.6%) had decreased
their dose, 627 (27.0%) had no change, and 1006 (43.4%) had
increased their dose during the study. Average age was 57.2
years. Patients in the no-change group were younger than
patients in the other two groups (mean age 55.6 vs. 60.1 and
57.2). Over two-thirds of patients in each group were female.
The no-change group had higher PMPM medical and pharmacy
costs ($2236.90 and $211.94) compared with the increased dose
($1719.80 and $186.09) and decreased dose groups ($1326.90
and $183.64). The difference in PMPM medical costs was sig-
niﬁcant after adjusting for age, gender, and risk score. PMPM
pharmacy costs were not statistically different. CONCLUSION:
Patients with no change in dose had the highest medical costs.
However there were no signiﬁcant differences in pharmacy costs.
Further research to explore the reasons for the differences in
medical costs and the impact of dose changes on clinical and
humanistic outcomes is recommended.
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IMPACT OF ANTI-TUMOR NECROSIS FACTORS ON HEALTH
CARE COSTS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Tang B1, Rahman MI1, Stephenson JJ2, Quimbo R2,Thompson HC1,
Dabbous O1
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OBJECTIVES: To evaluate the impact of anti-tumor necrosis
factor (TNF) therapy on health care costs in rheumatoid arthritis
(RA) patients. METHODS: Two groups of patients were identi-
ﬁed using claims data from Blue Cross Blue Shield health plans:
Group A-RA patients who initiated anti-TNF therapy (adali-
mumab, etanercept or inﬂiximab) between January 1, 2003 and
June 30, 2005; Group B-RA patients without anti-TNF therapy.
The groups were matched for gender, age and geographic region
(3 controls: 1 anti-TNF user). The index date for Group A was
deﬁned as the date of ﬁrst anti-TNF therapy; Group B patients
were assigned the index date of their matched case. All patients
were continuously enrolled for >=6 months before and >=12
months after the index date. RA-related and total health care
expenditures, excluding anti-TNF drug cost, were calculated for
the pre- and post-index periods. Multivariate analyses, control-
ling for potential confounders, were performed to compare per-
member-per-month (PMPM) expenditures. RESULTS: In total,
9545 RA patients were included (2405 in Group A and 7140 in
Group B); 70.5% were female and the average age was 48.0
years. In the pre-index period, Group A had higher RA-related
PMPM ($211 versus $32, p < 0.0001) and total health care costs
($711 versus $503, p < 0.0001) than Group B. Compared with
the pre-index period, RA-related PMPM costs (excluding anti-
TNF drugs) decreased for Group A by $44 (-20.9%) but
increased for Group B by $3 (+9.5%) (p = 0.0332) during the
post-index period. After adjusting for confounding variables,
RA-related cost differences from pre- to post-index period
remained between anti-TNF users and controls (p = 0.0049).
CONCLUSION: Although their pre-index RA-related costs were
signiﬁcantly higher, post-index RA-related costs (excluding anti-
TNF drug costs) of RA anti-TNF users decreased signiﬁcantly
from pre-index costs compared with RA non-anti-TNF user
costs. Additional analyses using clinical and quality-of-life
measures are needed to determine the effectiveness of anti-TNF
therapies.
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COST-EFFECTIVENESS OF RITUXIMAB (MABTHERA)
COMPARED WITH ABATACEPT (ORENCIA) FORTHE
TREATMENT OF MODERATE/SEVERE RHEUMATOID
ARTHRITIS (RA) INTHE UNITED KINGDOM
Lewis G1, Kielhorn A2, Diamantopoulos A3
1Roche Products Limited,Welwyn Garden City, Herts, UK, 2F.
Hoffmann-La Roche AG, Basel, Switzerland, 3IMS Health, London, UK
OBJECTIVES: To evaluate the cost-effectiveness of rituximab
compared to abatacept for the treatment of moderate/severe RA
patients following the failure of one previous TNF-inhibitor from
the perspective of the UK. METHODS: A cost-utility approach
was adopted, evaluating the total direct NHS costs and QALYs.
Baseline patient characteristics were based on the REFLEX phase
III trial. A micro-simulation model of 10,000 RA patients esti-
mated lifetime Health Assessment Questionnaire (HAQ) progres-
sion, QALYs and direct costs. The starting time-point of the
model was upon commencement of treatment with abatacept or
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